Uterine (Endometrial) Cancer clinical trials
224 active trials name this condition (recorded in the registry as “Endometrial Carcinoma”) . Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
- ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
- A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
- Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
- Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
- MCC-24-GYN-11: Comparison of Nodal Sampling in Endometrial Cancer
- Tirzepatide in Obesity-Driven Endometrial Cancer
- Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
- Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Pipelle vs the Curved Aspirator Device
- PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
- ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- ALPINE: Maintenance Letrozole/Abemaciclib
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- Uterine Preservation Via Lifestyle Transformation
- A Study of Ivonescimab in People With Endometrial and Cervical Cancers
- GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
- Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
- A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
- Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
- Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
- Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
- Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Activity Coaching During Pelvic Radiation Therapy
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- Vaginal Cuff Brachytherapy Fractionation Study
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- Sentinel Node Biopsy in Endometrial Cancer
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Study of EV for Recurrent Endometrial Carcinoma
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Endometrial Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.